TABLE 2.
Cases with discordant results between Amoy 9‐in‐1 and NGS (N = 10).
| Case | Age | Sex | Histology | Biopsy method | Amoy 9‐in‐1 | NGS | CDx confirmation | Molecular‐targeted therapy |
|---|---|---|---|---|---|---|---|---|
| 1 | 76 | F | Ad | TBB | MET Ex14 skip | (−) | Archer MET | Tepotinib |
| 2 | 65 | M | Ad | TBB | MET Ex14 skip | (−) | Archer MET | Tepotinib |
| 3 | 74 | M | Ad | TBB | MET Ex14 skip | (−) | NA |
MET inhibitor Clinical trial |
| 4 | 56 | F | Ad | TBB | ALK fusion | (−) | Oncomine | Alectinib |
| 5 | 44 | F | Ad | CNB | ALK fusion | (−) | ALK IHC | Alectinib |
| 6 | 66 | F | Ad | TBB | ROS1 fusion | (−) | Amoy ROS1 |
ROS1 inhibitor Clinical trial |
| 7 | 76 | F | Ad | TBB | ROS1 fusion | (−) | Amoy ROS1 |
ROS1 inhibitor Clinical trial |
| 8 | 70 | F | Ad | CNB | KRAS others | (−) | NA | NA |
| 9 | 75 | M | Ad | CNB | KRAS others | (−) | NA | NA |
| 10 | 77 | M | Ad | TBB | (−) | EGFR mutation E709_T710 > D | NA | NA |
Abbreviations: Ad, adenocarcinoma; Amoy ROS1, OncoGuide AmoyDx ROS1 gene fusions detection kit; Archer MET, Archer MET companion diagnostic system; CDx, companion diagnostic; CNB, core needle biopsy; EGFR, epidermal growth factor receptor; KRAS others, KRAS mutations besides G12C; NA, not applicable; NGS, next‐generation sequencing (Oncomine comprehensive assay [OCA] or Oncomine precision assay [OPA]); Oncomine, Oncomine Dx target test; TBB, transbronchial biopsy.